Trial Profile
An observational study comparing efficacy of natalizumab versus fingolimod as second line disease modifying treatment in patients with relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 17 Nov 2016 New trial record